<DOC>
	<DOCNO>NCT02094560</DOCNO>
	<brief_summary>To assess anti-tumor activity CAP7.1 base observe objective response rate rate disease stabilization , define primary secondary endpoint , patient NSCLC , SCLC biliary cancer progress despite one previous chemotherapy line .</brief_summary>
	<brief_title>CAP7.1 Treatment Advanced Stage , Therapy Refractory Lung Biliary Tract Tumors</brief_title>
	<detailed_description>A phase II evaluation perform adult patient parallel study 3 tumor type : NSCLC , SCLC Biliary Tract Cancer . All patient advance metastatic disease primary secondary resistance standard therapy . In tumor type patient randomize receive either therapy CAP7.1 best supportive care accord institution standard . Patient Control group progress may cross CAP7.1 , however patient analyze separately patient randomize CAP7.1 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histologically cytologicallyconfirmed , advanced disease document progression ( RECIST1.1 . ) one several chemotherapy line Patients may also receive molecular target therapy progress therapy completion Must recover acute reversible effect previous anticancer chemotherapy , usually 34 week myelosuppressive chemotherapy Serious concurrent medical condition , could affect compliance protocol interpretation result . Patients uncontrolled infection patient know infected human immunodeficiency virus ( HIV ) hepatitis infection eligible study Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>therapy refractory</keyword>
	<keyword>endstage</keyword>
	<keyword>solid tumour</keyword>
</DOC>